Award Notice for Single Donor, Type Specific, Universal Freeze-Dried Plasma Activities for Commercial Sustainability

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT942726CE047

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN13

Additional Details
Set Aside

NONE

Place of Performance

Maple Grove, Minnesota, UNITED STATES

SourceSAM
Documents1
The Defense Health Agency (DHA), a federal office under the Department of Defense, has issued an award notice for a new firm fixed price Research and Development contract. This contract is specifically focused on Product Lifecycle Management (PLM) activities to support the commercial sustainability of a Single Donor, Type Specific, universal Freeze-Dried Plasma (FDP) product. The FDP product in question is manufactured by Vascular Solutions LLC, a subsidiary of Teleflex Incorporated. The primary objective of this procurement is to ensure the ongoing viability and commercial readiness of the FDP product, which is critical for medical and defense applications. The scope of work encompasses all necessary PLM activities that contribute to maintaining the product’s lifecycle, including but not limited to research, development, and process optimization. The intended outcome is to sustain the product’s availability and reliability in the marketplace, thereby supporting the DHA’s mission to provide advanced medical solutions for defense personnel. This contract falls under the North American Industry Classification System (NAICS) code 541715, which pertains to Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). The Product Service Code assigned is AN13, further indicating a focus on research and development services. The place of performance is Maple Grove, Minnesota, United States, where Vascular Solutions LLC is located. The procurement was conducted under a justification and approval (J&A) for other than full and open competition, meaning the contract was awarded without a competitive bidding process. There are no set-aside requirements associated with this award, making it open to all qualified entities, though in this instance, the contract was directly awarded to Vascular Solutions LLC. Key requirements for this contract include the execution of PLM activities that are essential for the commercial sustainability of the FDP product. Expected deliverables involve maintaining the product’s lifecycle, ensuring regulatory compliance, and supporting ongoing research and development efforts to uphold product standards. For contractors interested in similar opportunities, it is important to note that the DHA is the contracting entity, and all communications regarding this notice should be directed to the primary contact, Toloria DuVall ([email protected]), or the secondary contact, Shannon Lertora ([email protected]). This award notice remains active and can be accessed via the SAM.gov portal using Opportunity ID b7086a2980654cb39648f38483a73395. Additional documentation, including a redacted justification and approval, is available through the provided link. Overall, this procurement underscores the DHA’s commitment to advancing medical technologies and sustaining critical products for defense health applications, with a particular emphasis on research and development in life sciences.